Ayesha Junaid

Ayesha Junaid


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AJAyesha Junaid
Ayesha Junaid
FYFizza Yousuf
Fizza Yousuf
RZRabia Zafar
Rabia Zafar
JTJaveria Taj
Javeria Taj
HYHermann Yokolo
Hermann Yokolo
Introduction and Importance: Androgen-producing tumors are rare in females, typically arising from the ovaries or adrenal glands. Sertoli–Leydig cell tumors (SLCTs) are uncommon sex cord-stromal ovarian tumors that cause hyperandrogenism, leading to virilization symptoms such as hirsutism, deep voice, and amenorrhea. Their rarity and similarity with other androgen-secreting conditions make diagnosis challenging. This case report describes an SLCT in a 16-year-old girl, underscoring the value of early diagnosis and fertility-sparing surgery. Case Presentation: A 16-year-old girl presented with secondary amenorrhea, hirsutism, and voice deepening. Hormonal workup revealed elevated testosterone and low sex hormone-binding globulin. Imaging identified a solid mass in the left ovary. Adrenal causes were excluded via hormonal assays and imaging. The patient underwent a laparotomy with left salpingo-oophorectomy. Histopathology confirmed a moderately differentiated SLCT, and immunohistochemistry was positive for inhibin and calretinin. Postoperative CT showed no metastasis. She required no chemotherapy and remained under regular follow-up. Clinical Discussion: SLCTs represent less than 1% of ovarian tumors and primarily affect young women. They often present with signs of androgen excess. Diagnosis relies on clinical, hormonal, imaging, and histological data. DICER1 gene mutations are frequently associated. Surgical excision is the standard treatment, with fertility-sparing options preferred in early stages. Chemotherapy is reserved for advanced or poorly differentiated cases. Conclusion: SLCT is a rare but treatable ovarian tumor. Early detection of androgen excess is crucial. Surgery is effective, and fertility can be preserved. Larger registries are needed to enhance disease understanding and management strategies.

10 August 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
AMAdeena Musheer
Adeena Musheer
MMMuhammad S. Mannan
Muhammad S. Mannan
MKMuhammad W. Khan
Muhammad W. Khan
AJAyesha Junaid
Ayesha Junaid
TBTuba Basit
Tuba Basit
MSMoazzam Shahzad
Moazzam Shahzad
Objectives: Durvalumab consolidation following concurrent chemoradiotherapy (CRT) has become the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). However, survival outcomes reported in clinical trials and real-world studies have been inconsistent, making it difficult to understand the efficacy and safety of this treatment modality fully. Our study aims to pool the available evidence to evaluate the impact of durvalumab in patients with unresectable stage III NSCLC. Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for studies including randomized controlled trials and real-world observational studies that assess durvalumab after definitive CRT in unresectable stage III NSCLC, till January 2026. Data extracted included median overall survival (OS), median progression-free survival (PFS), and survival rates. Random-effects meta-analyses were performed to pool OS and PFS. Results: A total of 3 studies comprising 861 patients with unresectable stage III NSCLC were included. Durvalumab consolidation after definitive CRT showed no statistically significant effect on OS (HR: 1.06, 95% CI: 0.52-2.14; I ²=51.6%; P =0.1268) or PFS (HR: 0.87, 95% CI: 0.45-1.68; I ²=49.6%; P =0.1374). Heterogeneity was moderate for both outcomes. In addition to these primary outcomes, multiple secondary efficacy and safety outcomes were systematically evaluated, including overall response rate and treatment-related adverse effects. Conclusions: Durvalumab consolidation demonstrates a favorable safety profile, but outcomes remain variable across studies. These findings highlight the importance of biomarker-driven patient selection and prospective real-world evaluation to maximize the clinical benefit of durvalumab in unresectable stage III NSCLC.